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A B S T R A C T
Introduction: Rivaroxaban selectively inhibits factor Xa (FXa), which plays a central role in blood coagulation. In
addition, FXa activates protease-activated receptor-2 (PAR-2). We have shown that PAR-2−/− mice exhibit less
cardiac dysfunction after cardiac injury.
Material and methods: Wild-type (WT) and PAR-2−/− mice were subjected to left anterior descending artery
(LAD) ligation to induce cardiac injury and heart failure. Mice received either placebo or rivaroxaban chow
either starting at the time of surgery or 3 days after surgery and continued up to 28 days. Cardiac function was
measured by echocardiography pre-surgery and 3, 7 and 28 days after LAD ligation. We also measured antic-
oagulation, intravascular thrombi, infarct size, cardiac hypertrophy and inflammation at various times.
Results: Rivaroxaban increased the prothrombin time and inhibited the formation of intravascular thrombi in
mice subjected to LAD ligation. WT mice receiving rivaroxaban immediately after surgery had similar infarct
sizes at day 1 as controls but exhibited significantly less impairment of cardiac function at day 3 and beyond
compared to the placebo group. Rivaroxaban also inhibited the expansion of the infarct at day 28. Rivaroxaban
did not significantly affect the expression of inflammatory mediators or a neutrophil marker at day 2 after LAD
ligation. Delaying the start of rivaroxaban administration until 3 days after surgery failed to preserve cardiac
function. In addition, rivaroxaban did not reduce cardiac dysfunction in PAR-2−/− mice.
Conclusions: Early administration of rivaroxaban preserves cardiac function in mice after LAD ligation.
1. Introduction
Myocardial infarction (MI) leads to an abrupt loss of cardiomyocytes
due to necrosis and apoptosis. The border zone around the infarct
contains cardiomyocytes that may ultimately die leading to an expan-
sion of the initial infarct. For instance, formation of intravascular
thrombi may reduce blood flow in the border zone. The change in
loading conditions after a MI triggers a compensatory cardiac re-
modeling in the myocardium [1]. Early remodeling begins within hours
after the initial infarct [1]. The ensuing cardiac remodeling of the in-
farcted area results in ventricular dilation, thinning of the affected wall
and an increase in wall stress that also induces remodeling of the non-
infarcted remote myocardium to preserve stroke volume [2,3].
However, myocytes that have undergone pathologic hypertrophy to
counteract unfavorable loading conditions eventually die leading to
heart failure [1].
There are two animal models of MI in which the left anterior des-
cending (LAD) coronary artery is either permanently ligated (LAD
model) or is transiently ligated (ischemia-reperfusion [I/R] model).
Tissue factor (TF) and coagulation proteases have been shown to con-
tribute to cardiac injury. For instance, inhibition of the TF-factor (F)
VIIa complex, factor Xa (FXa) or thrombin has been shown to reduce
infarct size and no-reflow in rabbit, rat and mouse I/R models [4–8].
Inhibitors of TF or thrombin inhibitors also reduced inflammation,
whereas the FXa inhibitor fondaparinux did not affect inflammation
[4–7,9]. Immobilized fibrinogen can activate leukocytes by binding to
⁎ Corresponding author at: Division of Hematology and Oncology, Department of Medicine, 111 Mason Farm Road, 2312C Medical Biomolecular Research Bldg., CB#7126, University 
of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
E-mail address: nmackman@med.unc.edu (N. Mackman).
https://doi.org/10.1016/j.thromres.2018.05.015
Received 27 March 2018; Received in revised form 24 April 2018; Accepted 14 May 2018
Available online 17 May 2018
T
occlusion, the chest was sutured and closed in 2 layers. Mice recovered
on a water-jacketed warming blanket. Mice received buprenorphine
(50 μg/kg subcutaneously) for post-operative analgesia. The surgeon
was blinded to the genotype of the mice.
2.3. Measurement of the plasma level of rivaroxaban
Plasma rivaroxaban was measured by using a functional assay as
described [35] with some modifications. Briefly, 100 μL of chromogenic
substrate (Liquid anti-Xa substrate, Diagnostica Stago, Parsippany, NJ)
was added to 50 μL mouse plasma samples (1:2 dilution) in imidazole
buffer and incubated for 60 s before adding 100 μL of STA® Liquid Anti-
Xa (Diagnostica Stago). The change in optical density was determined
at 405 nm from 90 to 120 s. The logarithmic measurement was ex-
pressed as a function of the linear concentration. A standard curve was
generated using a range of rivaroxaban concentrations (5–640 ng/mL)
(Sigma-Aldrich, St Louis, MO). Imidazole buffer was used to dilute
samples and standards. Results were expressed as a rivaroxaban con-
centration (ng/mL).
2.4. Measurement of the prothrombin time
Blood was collected into syringes containing sodium citrate (final
concentration: 0.38%, RICCA chemical company, Arlington, TX, USA)
from the infrarenal vena cava. Plasma was prepared by centrifugation
of the blood at 4500×g for 15min and stored at −80 °C. The pro-
thrombin time (PT) was determined using a 1-stage clotting assay with
mouse plasma, Thromboplastin D reagent (Thermo Fisher Scientific,
Waltham, MA) and a Start 4 Clotting Machine [36] (Diagnostica Stago).
2.5. Fibrin(ogen) staining
Paraffin-embedded heart sections were deparaffinized with antigen
retrieval. Slides were blocked with 3% bovine serum albumin (Sigma
Ardrich, St. Louis, MO, USA) in phosphate-buffered saline (Thermo
Fisher Scientific, Waltham, MA, USA) for 30min at room temperature.
Sections were incubated overnight at 4 °C with 10 μgmL−1 peroxidase
labeled anti-fibrin antibody (clone 59D8), a gift from Dr. Charles T.
Esmon, Oklahoma Medical Research Foundation. Fibrin staining
(brown) was detected using the DAB substrate (Agilent Technology,),
which was added for 2.5min. Sections were counterstaining with he-
matoxylin (Thermo Fisher Scientific) for 1min.
2.6. Measurement of inflammatory mediators and myeloperoxidase
Hearts were extracted immediately after euthanizing the mice and
cut along the short axis at the level of the LAD ligation. The section
below the LAD ligation was used for protein analysis. Hearts were
homogenized in RIPA buffer with phosphatase and protease inhibitors
as described [13,37]. IL-6, IL-1β, and myeloperoxidase (MPO) protein
levels in the hearts were measured with ELISA kits (R&D systems,
Minneapolis, MN).
2.7. Measurement of plasma cardiac troponin-I
Blood was collected from the retroorbital sinus into sodium citrate
(final concentration, 0.38%). The troponin-I concentration in plasma
was measured using a mouse cardiac troponin-I ELISA kit (Life
Diagnostics, West Chester, PA) [15,37].
2.8. Measurement of infarct size
For the measurement of infarct size at day 1, whole hearts were cut
into 1mm slices in the short axis. Viable and necrotic and apoptotic areas
were identified by incubating the hearts in 1% 2,3,5-
Triphenyltetrazolium chloride (TTC) (Sigma-Aldrich) for 30min at 37 °C
the integrin αMβ2 [10]. In addition, a fibrin degradation product called 
E1 enhances I/R injury by facilitating the recruitment of neutrophils 
into the myocardium [11]. These studies indicate that the coagulation 
cascade contributes to cardiac injury after a MI.
Coagulation proteases and other proteases activate protease-acti-
vated receptors (PARs), which comprise of 4 members PAR-1 to 4 [12]. 
FXa activates both PAR-1 and PAR-2 whereas thrombin activates PAR-
1, PAR-3 and PAR-4 [12]. PAR-1, PAR-2 and PAR-4 have been shown to 
play a role in cardiac injury and remodeling in the cardiac I/R injury 
model [6,13,14]. We have shown that PAR-2−/− mice have reduced 
inflammation and infarct size in an I/R injury model compared with 
controls [13]. We also found that PAR-2−/− mice had less cardiac in-
jury in the LAD model [15]. In contrast, the absence of PAR-1 did not 
affect the initial infarct size but reduced cardiac remodeling in an I/R 
injury model [6].
Neutrophils enhance cardiac injury after MI by releasing matrix 
metalloproteinases that contribute to infarct expansion by degrading 
intercellular collagen struts [16–18]. In addition, there is an increase in 
various inflammatory mediators, such as IL-1β, IL-6, and TNF-α, that 
contribute to cardiac injury [19,20].
Rivaroxaban selectively inhibits FXa [21]. It is a FDA-approved oral 
anticoagulant used for the prevention and treatment of venous throm-
boembolism, and the prevention of stoke in patients with atrial fi-
brillation [22]. Rivaroxaban has been studied in a variety of animal 
models. It reduces thrombosis [23,24], and was associated with less 
bleeding compared to warfarin in a tissue-type plasminogen activator 
stroke model [25,26]. In addition, rivaroxaban reduces pressure-in-
duced atrial fibrosis, atherosclerosis, diabetic nephropathy, neovascu-
larization in diabetic mice and inflammation in sickle cell disease 
[27–32]. Interestingly, rivaroxaban reduced PAR-1 and PAR-2 expres-
sion in a stroke model and in diabetic nephropathy [25,30]. PAR-2−/− 
mice had reduced diabetic nephropathy and inflammation in the sickle 
cell disease model [30,32], which is similar to the phenotype of wild-
type (WT) mice treated with rivaroxaban. These studies suggest that 
rivaroxaban may reduce PAR-2 signaling.
In this study, we examined the effects of rivaroxaban on cardiac 
function in mice after cardiac injury induced by LAD ligation. We chose 
the LAD model for these studies because it does not contain a re-
perfusion phase that affects the size of the initial infarct.
2. Material and methods
2.1. Mice
All studies were performed in accordance with the guidelines of the 
Institutional Animal Care and Use Committee of the University of North 
Carolina at Chapel Hill and in compliance with National Institutes of 
Health guidelines. We used male C57BL/6J (WT) mice as well as PAR-
2−/− mice [33] and PAR-2+/+ (a sister line to the knock-out mice) 
between 8 and 12 weeks of age. Mice were fed rivaroxaban chow 
(0.5 g/kg chow) (Bayer AG, Leverkusen, Germany), which gives an 
estimated dose of 80 mg/kg/day based on normal feeding, or matching 
placebo chow (Dyets, Bethlehem, PA). Mice were given rivaroxaban 
chow immediately after recovery from anesthesia after LAD ligation or 
sham surgery. In a second experiment, rivaroxaban chow was started on 
day 3 after LAD ligation.
2.2. LAD ligation
LAD ligation was performed as previously described [15,34]. 
Briefly, mice were anesthetized with an intraperitoneal injection of 
ketamine and xylazine (100 and 15 mg/kg, respectively). Mice were 
orally intubated to provide artificial ventilation (140–180 μL tidal vo-
lume, 130–140 breaths/min). Following a left thoracotomy at the 
fourth intercostal space, the LAD was ligated with an 8–0 nylon surgical 
suture 2 mm from the distal tip of the left atrium. Following the
followed by 4% paraformaldehyde for 30min at room temperature. Each
section was weighed and photographed under a SZX12 microscope
(Olympus Corporation, Tokyo, Japan) from both sides. The total area and
necrotic area were traced and calculated by computer planimetry
(Image J, NIH, version 1.21). Total infarct size was calculated
as [(A1xW1)+ (A2xW2)+…+(AnxWn)] / [(T1xW1)+ (T2xW2)+…+
(TnxWn)], for n slices, where A is the area of infarct for the slice denoted
by the subscript, T is the total area of the slice, and W is the weight of the
respective slice.
For the measurement of infarct size at day 28, five sections were
prepared from each heart and stained with Masson's trichrome. The
section with the largest infarct diameter was chosen and the blue fi-
brotic area of the infarcted myocardium and the red area of the un-
affected myocardium were analyzed by computer planimetry and the
percentage of scar to the total area was calculated.
2.9. Echocardiography
Echocardiography was performed prior to cardiac injury and after
cardiac injury on days 3, 7 and 28 using a Vevo 2100 ultrasonographic
system (VisualSonics, Toronto, CA). Left ventricle (LV) function was
measured by M-mode echocardiography derived from the long-axis
parasternal plane at the mid-ventricular level. Interventricular septum
thickness, posterior wall thickness and left ventricular diameter were
measured in systole and diastole. The ejection fraction (EF) and per-
centage of fractional shortening (FS) were calculated from the mea-
sured dimensions. Echocardiography data were read and interpreted by
W.B., who is a board-certified cardiologist.
2.10. Data analysis
All statistical analyses were performed using GraphPad Prism, ver-
sion 5.0 (GraphPad Software Inc., La Jolla, CA) or SAS v9.2 (SAS, Cary,
NC). Normally distributed data with equal variance was analyzed by
one or two way ANOVA (multiple group comparison; Bonferroni Post
Hoc analysis corrected for repeated measures over time) or a two-tailed
Student's t-test (two group comparisons) where appropriate. Data are
expressed as mean values ± the standard error of the mean. Nominal
data was analyzed by Chi-squared test. Log-rank analysis was used to
determine statistical significance of the survival of the different mice.
Differences were determined to be statistically significant at a p value
of< 0.05.
3. Results
3.1. Anticoagulant activity of mice receiving rivaroxaban
Cardiac injury was induced in mice by permanent ligation of the
LAD. The mice were given either placebo or rivaroxaban chow starting
immediately after LAD ligation. Mice started eating chow 6–8 h after
surgery. We observed similar plasma levels of rivaroxaban at day 1 in
the sham and LAD groups (Fig. 1A). Similar data were observed at day
28 (data not shown). To assess the impact of rivaroxaban on coagula-
tion, we measured the PT. The PT is considered more sensitive than the
activated partial thromboplastin time to determine the anticoagulant
effect of rivaroxaban [32]. Rivaroxaban significantly increased the PT
1 day after LAD ligation compared with the group receiving placebo
(Fig. 1B). Next, we determined if rivaroxaban affected intravascular
coagulation. We observed intravascular thrombi in 3 of 4 LAD ligated
mice receiving placebo (2 in the left atrium and one in a small vessel)
compared with 0 of 4 LAD ligated mice receiving rivaroxaban
(p= 0.03) (Fig. 1C). Taken together, these data indicate that the mice
were anticoagulated with rivaroxaban after LAD ligation.
3.2. Measurement of infarct size after LAD ligation
To assess the extent of myocardial injury in our model, we measured
infarct size 1 day after LAD ligation. Importantly, there was no differ-
ence in infarct size between the mice receiving rivaroxaban or placebo
(Fig. 2A). Plasma troponin-I was used as a surrogate marker of infarct
size after LAD ligation. Again, there was no difference in troponin-I
levels between rivaroxaban and placebo treated mice after LAD ligation
(Fig. 2B). Consistent with previous reports [38,39], we observed a high
rate of mortality (40%) after surgery between days 4 and 6 due to
rupture of the LV (Supplementary Fig. 1). However, there was no dif-
ference in mortality between the two groups.
We also measured the infarct size at day 28. In contrast to the results
from day 1, we observed a significantly smaller infarct in the mice
treated with rivaroxaban compared with mice that received placebo
(Fig. 2C and D). This indicates that rivaroxaban is inhibiting the ex-
pansion of the initial infarct.
3.3. Effect of rivaroxaban on inflammation and neutrophil recruitment after
LAD ligation
We measured several inflammatory cytokines in the hearts of mice
2 days after LAD ligation. There were no significant differences in the
levels of IL-6, IL-1β, and TNF-α in injured mice treated with
Fig. 1. Anticoagulating mice with rivaroxaban. (A) Rivaroxaban (Riva) plasma concentrations on day 1 in mice subjected to left anterior descending artery (LAD)
ligation or mice with a sham operation fed either placebo (white bars) or Riva (black bars) diet (n= 3 sham, n= 3 LAD placebo, n= 5 LAD Riva). (B) Prothrombin
time (PT) on day 1 (n= 9 per group) in mice subjected to LAD artery ligation fed either placebo (white bars) or Riva (black bars). Data are presented as
mean ± SEM. *p < 0.05. (C) Presence of an intravascular thrombi stained with fibrin(ogen) in the left atrium 24 h after LAD ligation in mice receiving placebo.
Original magnification×200, bar= 100 μm.
rivaroxaban compared to those treated with placebo (Fig. 3A–C). We
also measured MPO levels as a marker of neutrophil infiltration. Again,
there was no difference in the levels of MPO between the two groups
(Fig. 3D). These data suggest that rivaroxaban does not significantly
reduce the expression of inflammatory mediators or the recruitment of
neutrophils two days after LAD ligation.
3.4. Effect of rivaroxaban on heart hypertrophy
The heart weight/tibia lengths (HW:TL) ratio was calculated as a
marker of hypertrophy and was found to be significantly increased at 7
and 28 days after LAD ligation in mice receiving placebo compared to
sham operated mice (Fig. 4). Mice treated with rivaroxaban after LAD
ligation had less hypertrophy than the placebo group but the difference
was not statistically significant (Fig. 4).
3.5. Rivaroxaban preserves cardiac function after LAD ligation
To determine the effect of rivaroxaban on cardiac remodeling, we
assessed cardiac function and wall thickness by echocardiography prior
to LAD ligation and 3, 7 and 28 days after LAD ligation in mice given
placebo or rivaroxaban on day 0. The EF and FS of placebo-treated mice
subjected to LAD ligation were significantly reduced compared to sham
operated mice beginning on day 3 and continuing up to day 28 after
LAD ligation (Fig. 5A) (Table 1). Mice treated with rivaroxaban had
significantly less reduction in the EF and FS compared to mice receiving
placebo (Fig. 5A) (Table 1). This effect was evident on day 3 and
continued throughout the 28-day experimental period (Fig. 5A)
(Table 1).
To assess the effects of the infarct on subsequent remodeling, the
interventricular septum (IVS), the opposing left ventricular posterior
wall (LVPW), and the left ventricular internal diameter (LVID) were
measured by echocardiography. The infarcted IVS, which is directly
Fig. 2. Effect of rivaroxaban on infarct size at day 1 and
28. (A) Comparison of infarct size on day 1 in mice
subjected to left anterior descending artery (LAD) liga-
tion and treated with either placebo (n= 7) or rivarox-
aban (n= 6). Infarct size was measured with computer
planimetry on 1mm heart slices stained with 2,3,5-
Triphenyltetrazolium chloride. (B) Troponin-I levels in-
creased due to LAD ligation. Both placebo (n= 18) and
rivaroxaban treated mice (n= 14) had significantly
higher troponin-I levels after LAD ligation compared to
sham operated mice (n= 6) on day 1. There was no
difference between placebo and Riva treated mice with
LAD ligation. Placebo: white bars, rivaroxaban: black
bars. Data are presented as mean ± SEM. #p < 0.05 vs.
sham. (C) Infarct size at day 28 in mice treated with ei-
ther placebo (white bar) (n=12) or rivaroxaban (black
bar) (n= 15). Data is presented as mean ± SEM.
*p < 0.05. (D) Representative images of hearts from
mice 28 days after LAD ligation and treated with either
rivaroxaban or placebo.
Fig. 3. Effect of rivaroxaban on the expression of inflammatory mediators and myeloperoxidase after cardiac injury. (A–C) IL-1β, IL-6 and myeloperoxidase (MPO)
were measured in either sham operated or left anterior descending artery (LAD) ligated mice fed either placebo or rivaroxaban (Riva) chow for 2 days (n= 3 sham
placebo, n= 3 sham Riva, n=9 LAD placebo, n= 7 LAD Riva). IL-6 and IL-1β, and MPO were significantly increased in LAD ligated mice. There was no difference
between placebo and rivaroxaban treated mice. The groups are placebo (white bars) and rivaroxaban (black bars). Data are presented as mean ± SEM, #p < 0.05
versus same treatment of sham mice.
supplied by the LAD, was severely thinned in hearts of both placebo and
rivaroxaban treated mice (Table 2). The LVPW was severely thinned in
placebo treated mice indicating global thinning of the heart. However,
the LVPW was thicker in rivaroxaban treated mice compared to con-
trols, suggesting that rivaroxaban may reduce the impairment of heart
function by protecting myocardium remote from the infarct (Table 2).
In addition, rivaroxaban treated mice had significantly less heart dila-
tion as indicated by a lower LVID compared to placebo treated mice
(Table 2). The differences between treatment groups were observed as
early as day 7 and persisted through day 28. These data suggest that
treatment with rivaroxaban after LAD ligation preserves EF and FS by
reducing pathologic remodeling of the LVPW and by reducing LV di-
lation.
To model the effect of rivaroxaban in patients with heart failure, we
performed a second experiment in which rivaroxaban was administered
beginning on day 3 after LAD ligation. Heart function was assessed by
echocardiography prior to LAD ligation and 3, 7 and 28 days after LAD
ligation. In contrast to the results observed when rivaroxaban was given
to the mice on day 0, there was no protective effect of rivaroxaban
when it was given on day 3 (Fig. 5B). These data indicate that rivar-
oxaban needs to be administered within the first three days after LAD
occlusion to exert its beneficial effects.
3.6. Effect of rivaroxaban on cardiac function after LAD ligation in PAR-2
deficient mice
Since FXa can activate PAR-2, we determined the effect of rivar-
oxaban on cardiac remodeling in PAR-2−/− mice subjected to LAD li-
gation. As expected from our previous study [15], placebo-treated PAR-
2−/− mice subjected to LAD ligation had less impairment of LV func-
tion compared with placebo-treated PAR-2+/+ mice (Fig. 6). Rivarox-
aban reduced the impairment of cardiac function in PAR-2+/+ mice but
not in PAR-2−/− mice after LAD ligation (Fig. 6).
4. Discussion
In this study, we found that early but not late administration of the
FXa inhibitor rivaroxaban reduces the impairment of cardiac function
in a mouse model of LAD ligation. Rivaroxaban is an anticoagulant that
specifically targets FXa. However, rivaroxaban may also reduce in-
flammation by inhibiting FXa activation of PAR-2. We found that riv-
aroxaban prolonged the PT and reduced intravascular coagulation, in-
cluding formation of thrombi in the left atrium, in mice subjected to
LAD ligation indicating the mice were anticoagulated. Other studies
have shown that rivaroxaban inhibits coagulation in mouse models. For
instance, it reduced TF-induced thrombosis in mice subjected to cardiac
I/R injury and also reduced thrombosis in a catheter model [23,24].
Another study showed that rivaroxaban abolished left atrial thrombus
formation in a mouse model of transverse aortic constriction that in-
duces pressure-overload-induced cardiac hypertrophy [27]. Therefore,
the protective effect of rivaroxaban may be, in part, due to its antic-
oagulant activity.
Fig. 4. Effects of rivaroxaban on hypertrophy after cardiac injury. Hearts and
lungs of sham operated mice and mice subjected to left anterior descending
artery (LAD) ligation and treated with placebo or rivaroxaban (Riva) were
analyzed on day 7 (n= 3 sham, n=9 placebo, n= 9 Riva) or day 28 (n= 3
sham, n= 6 placebo, n=4 Riva). The heart weight (HW) was measured and
normalized to tibia length (TL). There was an increase in heart hypertrophy
with LAD ligation at both time points but no statistical difference between the
two treatments was observed. Sham operated (striped bars), placebo/LAD li-
gated (white bars) rivaroxaban/LAD (black bars). Data are presented as
mean ± SEM; *p < 0.05.
Fig. 5. Rivaroxaban preserves ejection
fraction by decreasing cardiac remodeling.
Echocardiography was performed on the
different groups of mice on days 0, 3, 7 and
28. (A) Mice underwent either a sham op-
eration (n=3) or left anterior descending
artery (LAD) ligation and were treated with
placebo (n= 9) or rivaroxaban (n=9).
Placebo mice had a significantly reduced
ejection fraction (EF) compared to sham
operated mice at all time points. Mice that
underwent LAD ligation but were fed
Rivaroxaban (Riva) chow had a sig-
nificantly preserved EF compared to pla-
cebo mice on days 3, 7 and 28. (B) Mice underwent sham operation (n=3) or underwent LAD ligation with placebo (n= 11) or rivaroxaban treatment (n= 9)
beginning on day 3 after surgery. No difference between placebo and rivaroxaban treated groups was observed. Sham: circles; placebo/LAD: squares; rivaroxaban/
LAD: triangles. Data are presented as mean ± SEM; *p < 0.05.
Table 1
Echocardiographic data at baseline and after cardiac injury.
Sham LAD/P LAD/R LAD/P vs LAD/
R
EF (%) d 0 83.03 ± 2.7 82.9 ± 0.56 83.53 ± 1.91
d 3 83.63 ± 2.74 36.9 ± 2.78 51.25 ± 7.51 *
d 7 78.94 ± 3.76 29.61 ± 4.38 50.98 ± 6.37 **
d 28 87.7 ± 0.81 19.61 ± 3.86 40.86 ± 3.06 ***
FS (%) d 0 49.89 ± 3.1 49.58 ± 0.82 50.71 ± 2.12
d 3 50.78 ± 2.95 17.56 ± 1.52 26.32 ± 4.94 *
d 7 45.97 ± 3.57 14.05 ± 2.25 25.79 ± 3.86 **
d 28 55.91 ± 1.15 9.13 ± 1.88 20.08 ± 1.67 ***
Mice underwent either a sham operation (n= 3) or left anterior descending
(LAD) artery ligation and were treated with placebo (P) (n=9) or rivaroxaban
(R) (n=9) starting on day 0. Echocardiography was performed prior to cardiac
injury on day 0 and after cardiac injury on day 3, 14, and 28. Ejection fraction
(EF) and fractional shortening (FS) were calculated based on M-mode mea-
surements. Data are presented as mean ± SEM. 2-way ANOVA; *p < 0.05,
**p < 0.01, ***p < 0.001.
Rivaroxaban has been shown to be protective in a variety of mouse
models, including transverse aortic constriction, atherosclerosis, and
sickle cell disease [27,28,32,40]. Interestingly, rivaroxaban reduced
inflammation in these models. In addition, edoxaban, another member
of the class of oral FXa inhibitors, reduced inflammation and diabetic
retinopathy in a mouse model [30]. Surprisingly, we found that rivar-
oxaban did not affect the expression of inflammatory mediators or MPO
two days after LAD ligation. Two studies investigated the effect of the
FXa inhibitor fondaparinux in a rat model of cardiac I/R injury [8,9].
Interestingly, fondaparinux reduced infarct size without affecting in-
flammation. The protective effect of fondaparinux was dependent on
STAT-3 phosphorylation and was associated with increase expression of
thrombomodulin and endothelial cell protein C receptor [8,9].
In addition to its central role in blood coagulation, FXa can also
activate PAR-2 [12]. We and others have shown that PAR-2 activation
induces hypertrophy of cultured cardiomyocytes [15,41]. We found
that PAR-2−/− mice had reduced inflammation in the cardiac I/R
model compared to controls [13]. Furthermore, we showed that PAR-
2−/− mice have less cardiac impairment in the LAD model [15]. In
other studies, PAR-2−/− mice had reduced diabetic nephropathy,
atherosclerosis and inflammation in the sickle cell disease model
[30,32,42]. The fact that the phenotype of PAR-2−/− mice is similar to
wild-type mice treated with rivaroxaban in these three models suggests
that rivaroxaban may be acting by reducing pathological PAR-2 sig-
naling.
Consistent with these studies, we found that rivaroxaban did not
provide additional protection to PAR-2−/− mice in the LAD model. This
suggests that rivaroxaban may reduce expansion of the infarct after LAD
ligation, in part, by reducing pathological PAR-2 signaling. However,
we cannot exclude the possibility that there are two parallel pathways,
namely a FXa-thrombin-fibrin pathway and a PAR-2 pathway, that in-
dependently contribute to cardiac injury via different mechanisms.
Indeed, PAR-2 is activated by a variety of proteases, such as tryptase,
that are present during cardiac injury [43].
Taken together, our data suggest that rivaroxaban may be cardio-
protective via a combination of two activities - its anticoagulant activity
and its ability to inhibit pathological FXa-PAR-2 signaling. Inhibition of
coagulation would reduce intravascular thrombi and help preserve
blood flow to cardiomyocytes in the border zone around the infarct.
Reducing FXa-PAR-2 signaling would reduce hypertrophy of cardio-
myocytes and cardiac remodeling.
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